Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > The Key to Theralase ACT

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Apr 29, 2022 1:01pm

350 Views

Post# 34642815

RE:The Key to Theralase ACT

This is correct, the 2 factors that contribute to Tumor cell kill for PDT are the drug and the light activation. Getting the tumors to uptake sufficient drug requires that the tumors be in contact with the drug for a certain amount of time at a high enough concentration. That is why (as I have forwarded some ideas to management) it is Essential to have All surfaces of the bladder "Fully Immersed Continuously " for a minimum set period of time. That would mean that the patients would have to change positions during instillation of drug phase. Perhaps they are doing this already? But that may be a possible factor affecting efficacy? The light activation seems to be taken care of using maximum bladder volume which will allow for light to reach all areas of bladder. IMHO. As per Dr Lilge AUA presentation a few years back, the drug is rapidly taken up by cancer cells, but this still requires Full Immersion for a minimum amount of time especially if tumors are on the Anterosuperior surface of the bladder , then the patients need to get on all fours ( hands and knees) to get drug long enough in those areas. All IMHO. Let's Hope next few weeks/ months we get some nice updates and get our SP to hit $1.20 target or more.

Rumpl3StiltSkin wrote: Correct me, If I'm wrong. Is that it isn't a traditional drug. In how it works. Since it is Photo Activated, It should work at the cellular level, regardless of a persons(species) genetic make up. So we saw a very high % in test tube 99%. Also in rats, very high. low 90s% I think.

For NMIBC in humans it is more complicated, mainly due to how the shape of bladders differ, and that makes the dosimetry very complicated. Also, the patient population is mostly older and more frail.

My take is however long it takes TLT to get thru this Phase 2 trial and achieve FDA approval, they'll have an approved cancer drug that can be used off label, to treat other cancers, most other cancer indications will probably be less complicated that NMIBC.

The overall CR %s of other cancer indications could/should be quite high over time. As Dr.s and Clinicians get better at applying 1433, and eventually the super compounds, to future cancer indications.